Enterprise Value
-25.62M
Cash
133.6M
Avg Qtr Burn
-8.45M
Short % of Float
1.48%
Insider Ownership
11.77%
Institutional Own.
66.78%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CYT-0851 w/ capecitabine Details Cancer, Ovarian cancer | Failed Discontinued | |
CYT-0851 w/ gemcitabine Details Solid tumor/s, Cancer | Failed Discontinued |